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MEDICIS-PROMED aims to develop a network of academic, 
medical and industrial partners providing an extensive 
doctoral program to 15 young scientists in the field of new 
personalized treatments using radioisotope beams, notably 
for treatment of ovarian cancer. 
This field is expected to expand rapidly and provide new 
types of treatments combining imaging and personalized 
treatment with the same radiopharmaceutical and different 
types of isotopes, emitting positron or gamma light for 
imaging on one side, and Auger electron, beta and alpha 
radiation for treatment on the other side, known as 
theranostics pairs [1]. In addition, positron emitting isotopes 
such as 11Carbon can personalize hadron therapy treatments 
by imaging the dose distribution of the implanted ions [2,3]. 
In this scheme, CERN, the European Organization for Nuclear 
Research is the coordinating partner, and collaborates with 
local hospitals which are able to exploit short-lived isotopes 
produced in the newly constructed CERN-MEDICIS facility. It 
also fits within an extended network of high-technology 
companies and leading academic research institutes, which 
will design new components for the development or tests of 
innovative radiopharmaceuticals and imaging agents for 
personalized treatment. It brings world-class researchers 
together in the field of lasers and isotope mass separation, 
accelerators, material science, oncology, entrepreneurial 
radiopharmaceutical production, and imaging, to propose 
new solutions to the second deadliest cancer for women. 
The program will develop along three R&D work packages 
integrating multidisciplinary intersectorial training teams: 
• Development of new radioisotopes and techniques using 
isotope mass separation for medicine and based on CERN-
MEDICIS. 
• Development and test of 11Carbon PET-aided hadron 
therapy. 
• Synthesis & tests of radiopharmaceuticals to diagnose and 
treat ovarian cancer. 
Because of the unique capability of CERN-MEDICIS to produce 
medical batches of innovative isotopes, such as 149Terbium 
[4] and thanks and to the new generation of young scientists 
that will be trained in the relevant fields the MEDICIS-
PROMED innovative training network will significantly 
advance the use of radioisotopes for personalized medicine in 
Europe and go beyond the present common practices. 
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Purpose: Experimental data for the impact of fractionated 
proton beam exposures is limited. Using acute exposures, the 
current clinical adoption of a generic, constant cell killing 
RBE has been shown to underestimate the effect of the sharp 
increase in Linear Energy Transfer (LET) in the distal regions 
of the spread-out Bragg peak (SOBP).  Here we aim to 
investigate the clinical implications of a variable Relative 
Biological Effectiveness (RBE) on proton dose fractionation.  
Methods and Materials: Human fibroblasts (AG01522) were 
irradiated with 219.65 MeV protons at four depth positions 
along a clinical SOBP. These were delivered as fractionated 
regimes with an inter-fraction period of 24 hours at the 
Prague Proton Therapy Centre.  Cell killing RBE variations 
were measured using standard clonogenic assays and were 
further validated using Monte Carlo simulations and 
parameterized using a Linear-Quadratic formalism. 
Results: Consistent with previous studies of a single fraction 
response for both survival and DNA damage (DSB foci) (1,2), 
significant variations in the cell killing RBE for fractionated 
exposures along the proton dose profile were observed.  The 
RBE increased sharply towards the distal position, 
corresponding to a reduction in the cell sparing effectiveness 
of fractionated proton exposures at lower energies and 
higher LET.  The effect is more pronounced at smaller doses 
per fraction. Experimental survival fractions were adequately 
predicted using a Linear Quadratic formalism assuming full 
repair between fractions.  The data were also used to 
validate a parameterized variable RBE model based on linear 
alpha parameter response with LET that showed considerable 
deviations from clinically predicted isoeffective fractionation 
regimes. 
Conclusions: The biologically effective dose calculated using 
the clinically adopted generic RBE of 1.1 significantly 
underestimates the biological effective dose from variable 
RBE for single and fractionated regimes with low doses per 
fraction.  Coupled with an increase in effective range in 
fractionated exposures, the study indicates the needs for the 
optimization of proton therapy particularly in the move 
towards hypofractionation. 
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Purpose of this work: Nowadays it is well assessed that the 
particle track structure plays a key role in the damage of 
living cells1. Therefore, the quantification of the dose within 
nanometric volumes is of paramount importance for 
characterizing the effectiveness of cancer treatments with 
ion beams. There are currently several facilities suitable for 
the detailed on-line analysis of the number of ionizations left 
by an impinging ions into nanometer equivalent gas 
volumes.2,3 Nonetheless, the realization of a portable system 
for nanodosimetry  quantification would be extremely useful 
for the dose control in treatment plants. In this work we 
propose the use of Single Photon Avalanche Diode (SPAD) 
arrays for the luminescence imaging of quantum dots (QDs) 
structures.4 In particular, the analysis of QD layers will be 
performed before and after ion irradiation in order to study 
how the released dose affects the optical properties of the 
system. 
Materials and methods: The luminescence of CdSe/ZnS QD 
layers is excited with a pulsed LED (475 nm central 
wavelength and 20 ns pulse width).5 The luminescence light 
is collected with a high-numerical aperture optics and 
delivered to the detector through an optical filter to 
eliminate the residual scattered excitation light (Figure 1a). 
A SPAD pixel array6 is placed in the focal plane to collect the 
fluorescence map of the sample under analysis. The light 
signal is collected in time-gated mode in order to measure 
the QD lifetime before and after irradiation (Figure 1b). 
Moreover, time-gated detection can be used as a time-
domain excitation filtering technique, thus simplifying the 
design of a portable and compact nanodosimeter. 
Results: The luminescence intensity and lifetime of QD 
irradiated with different fluencies of 2.0 MeV protons and X-
rays will be studied and compared with non-irradiated 
samples. The changes in light yield and lifetime will be 
correlated to the damage released by the impinging radiation 
through Monte Carlo calculations. 
Conclusions: Although SPAD arrays have already been 
employed in the past for the sensing of QD luminescence, 
this is the first time that QD lifetime measurements is 
proposed as a probing tool applied to nanodosimetry. This 
preliminary study will give an experimental confirmation on 
the validity of the idea.  
 
 
 
Figure 1. (a) Simplified system diagram (b) Illustration of 
time gated detection principle 
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Purpose: One of the main goals of radiotherapy is to achieve 
tumor control and minimize probability of normal–tissue 
complications. For this reason radiation oncology requires 
high accuracy, which implies no more than 2 – 3% uncertainty 
levels in the treatment planning calculations [1]. That is 
challenging, when heterogeneous tissues such as lungs and 
bones are involved [2,3]. To verify the accuracy of the dose 
calculation algorithms numerous approaches might be 
performed. The most common are point dose, one-
dimensional profile and two-dimensional isodose line 
comparison with experimental measurements [3]. 
Materials/Methods: In presented study, results of transport 
modeling and the deposited spatial distribution of the dose, 
obtained by Anisotropic Analytical Algorithm (AAA) and Pencil 
Beam Convolution algorithm (PBC), were compared to 
measurements recorded during the experiment. To achieve 
meaningful conclusions, three parameters: dose difference 
(DD), distance to agreement (DTA) and gamma parameter (γ) 
were taken into consideration and examined. The irradiation 
was performed using CIRS anthropomorphic phantom. For 
dose detection gafchromic EBT films were used and scanned 
after exposure using Epson Scanner. Measured and planned 
dose distributions were analyzed via FilmQA software.  
Results and Conclusions: Preliminary results showed that the 
AAA, with its complex accounting of heterogeneities, 
provides more accurate dose calculation within an area of a 
high density gradient, than PBC does. The level of the data 
